SEC Tracker
Get the app

Maze Therapeutics MAZE

Charles J Homcy - Insider ownership filing (4)

Charles J Homcy, insider filing for Maze

Form
4
Filed
Importance
Routine
  1. Insider ownership filing (4)
  2. Reports beneficial ownership changes

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Maze Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  2. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. CytoDyn CYDY public float $418M, Nov 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.